SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics
technology, today announced the launch of its high-plex proteomics
platform, which provides 11,000 total protein measurements. The
SomaScan 11K Platform is the largest proteomics offering available
on the market.
The new high-plex platform is expected to give resesarchers a
considerable edge in the discovery of biomarkers and drug targets
for translational medicine. Proteins make up more than 90% of all
known drug targets and having a broader view of the human proteome,
provided by SomaLogic’s 11K platform, gives researchers more
opportunities to make unique and novel biological discoveries. The
aptamer-based platform retains the previous version’s low
coefficients of variation versus the 10-to-20% in antibody-based
platforms. This gives researchers more accuracy with fewer, smaller
samples, which is often critical in population studies with limited
sample sizes.
“Our research teams expanded the SomaLogic SomaScan Platform
from covering 7,000 proteins to 11,000 proteins—over half of the
human proteome,” said SomaLogic Chief Executive Officer Adam Taich.
“Consistent with every expansion of our SomaScan menu size, our
scientists focused on maintaining the platform’s reproducibility,
sensitivity and specificity across a 10-log dynamic range.”
SomaLogic’s assay services lab in Boulder, Colo. is already
successfully running the SomaScan 11K Platform. In addition,
selected authorized sites are running the expanded platform, with
new sites expected to come online throughout Q4. SomaLogic’s
authorized sites around the world will begin offering the expanded
platform in late 2023 and into 2024. The Houston OMICs
Collaborative (HOC) at the University of Houston will be the newest
authorized site to offer the SomaScan 11K Platform.
“We aim ultimately to measure the entire proteome in order to
identify the most specific biomarkers and to generate deeper
insights into the pathophysiological mechanisms underlying human
disease or associated with therapeutic response. Measuring an
additional 3,500 proteins on the 11K assay is anticipated to
provide new biomarkers that we were not able to measure previously
which could help to develop diagnostics with higher accuracy,” said
Towia Libermann, Ph.D., Director Beth Isreal Deaconess Medical
Center Genomics, Proteomics, Bioinformatics, and Systems Biology
Center and DF/HCC Cancer Proteomics Core, which has run the
SomaScan Assay since 2015.“The SomaScan Assays have allowed us to
study human biology at scale from individuals to large populations
of people, and the expanded platform will help us uncover many new
secrets,” said Tony Wyss-Coray, PhD, Director of the Phil and Penny
Knight Initiative for Brain Resilience at Stanford University. “We
are particularly excited about the addition of several hundred new
probes detecting proteins highly or exclusively expressed in
nervous tissue and the brain.”
The expansion of the SomaScan 11K Platform followed accredited
quality assurance standards at SomaLogic, including ISO 9001:2015,
ISO 15189:2012 and ISO 27001:2013. SomaLogic’s assay lab in
Boulder, Colo. is also a CAP-accredited and CLIA-certified lab.
For more than twenty years, SomaLogic has grown from its roots
in the research lab to become a global leader in proteomics with
technology that delivers the quality and quantity of biological
insights scientists and researchers need - from lab to last mile.
This latest innovation offering is just another illustration of how
SomaLogic can help researchers and scientists make better, safer,
more targeted therapies and deliver them to market faster.
About SomaLogic SomaLogic is catalyzing
drug research and development and biomarker identification as a
global leader in proteomics technology. With a single 55 microliter
plasma or serum sample, SomaLogic can run 11,000 protein
measurements, covering more than half of the approximately 20,000
proteins in the human body. For more than 20 years we’ve supported
pharmaceutical companies, and academic and contract research
organizations who rely on our protein detection and analysis
technologies to fuel drug, disease, and treatment discoveries in
such areas as oncology, diabetes, and cardiovascular, liver and
metabolic diseases. Find out more at www.somalogic.com and follow
@somalogic on LinkedIn.
Forward Looking Statements This press
release contains certain forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
All statements, other than statements of historical fact included
in this press release, regarding our strategy, future operations,
financial position, estimated revenues, projections, prospects,
plans and objectives of management are forward-looking statements.
These forward-looking statements generally are identified by the
words “believe,” “project,” “forecast,” “guidance,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“continue,” “will likely result,” “possible,” “potential,”
“predict,” “pursue,” “target” and similar expressions, although not
all forward-looking statements contain such identifying words.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Forward-looking statements do not guarantee
future performance and involve known and unknown risks,
uncertainties and other factors. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including factors which are
beyond SomaLogic’s control. You should carefully consider these
risks and uncertainties, including, but not limited to, those
factors described under Part I, Item 1A – “Risk Factors” in our
Annual Report on Form 10-K and other filings we make with the
Securities and Exchange Commission. These filings identify and
address important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and SomaLogic assumes
no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Should one or more of these risks or
uncertainties materialize, or should any of the assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. The Company will not
and does not undertake any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities laws.
SomaLogic Media Contact Emilia Costales
720-798-5054 ecostales@somalogic.com
SomaLogic Investor ContactMarissa
BychGilmartin Group LLCinvestors@somalogic.com
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024